The identification of patient subgroups who will benefit most from such strategies is also required – DDR proteins such as DNA-PKcs have been suggested to have a tumor-suppressive role in the early stages of carcinogenesis where ineffective DDR may contribute to the generation of genomic instability that drives tumor progression (99). The gene discussed is DDR1; the disease is neoplasm.